Upstream Bio (UPB) to Release Earnings on Wednesday

Upstream Bio (NASDAQ:UPB) will likely be issuing its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $0.5220 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 19, 2026 at 12:30 PM ET.

Upstream Bio Price Performance

NASDAQ:UPB opened at $8.06 on Tuesday. The firm’s 50-day moving average price is $21.50 and its 200-day moving average price is $22.30. The company has a market capitalization of $435.56 million, a PE ratio of -4.29 and a beta of 3.00. Upstream Bio has a 1-year low of $5.14 and a 1-year high of $33.68.

Analyst Ratings Changes

UPB has been the topic of several research reports. Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Evercore began coverage on Upstream Bio in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 price target on the stock. Finally, Lifesci Capital started coverage on Upstream Bio in a research note on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Upstream Bio has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Institutional Trading of Upstream Bio

A number of institutional investors and hedge funds have recently bought and sold shares of UPB. AQR Capital Management LLC purchased a new position in Upstream Bio in the first quarter worth about $115,000. Woodline Partners LP lifted its stake in shares of Upstream Bio by 5.8% in the first quarter. Woodline Partners LP now owns 557,063 shares of the company’s stock worth $3,409,000 after buying an additional 30,552 shares in the last quarter. Creative Planning purchased a new stake in shares of Upstream Bio during the second quarter valued at approximately $154,000. JPMorgan Chase & Co. grew its holdings in shares of Upstream Bio by 8.4% during the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after buying an additional 1,275 shares during the last quarter. Finally, Legal & General Group Plc increased its position in shares of Upstream Bio by 83.0% during the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after acquiring an additional 1,440 shares in the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.